LCD-L38988
Document details
Summary
The new LCD for Molecular Syndromic Panels will streamline the billing process for pathogen identification testing by establishing clear guidelines. This could potentially increase revenue for facilitNew guidelines for molecular testing could boost revenue.
Affected codes
ICD-10-CM
Affected specialty
Infectious Disease / Microbiology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38988&ver=18CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy LCD-L38331 · Infectious Disease / Microbiology
The Noridian LCD for Blood Product Molecular Antigen Typing effective from January 22, 2026, could substantially impact reimbursement for labs specializing in this testing. Labs should prepare for upd
View alertPolicy LCD-L38333 · Infectious Disease / Microbiology
The effective date of the new MolDX guidelines for Blood Product Molecular Antigen Typing will shift billing requirements, potentially impacting reimbursement for impacted services. Providers should p
View alertPolicy LCD-L39001 · Infectious Disease / Microbiology
The implementation of this LCD on molecular syndromic panels will significantly influence billing practices for infectious disease testing. Providers will need to ensure they comply with the outlined
View alertPolicy LCD-L39003 · Infectious Disease / Microbiology
The new LCD regarding MolDX: Molecular Syndromic Panels for Infectious Disease may impact billing practices significantly for laboratories involved in pathogen identification testing. Providers should
View alert